Pramipexole: Price, Dosage & Where to Buy

Pramipexole is a non-ergot dopamine agonist prescribed for Parkinson's disease. It acts on dopamine receptors, helping support signalling involved in movement, and requires a prescription in the United Kingdom. It is also indicated for moderate-to-severe primary restless legs syndrome, with the treatment schedule depending on the condition being treated and kidney function.

Pramipexole belongs to a group of medicines called dopamine agonists. Dopamine is a chemical messenger that helps nerve cells communicate, including in brain pathways involved in controlling movement. Dopamine agonists stimulate dopamine receptors, mimicking some of dopamine's actions rather than supplying dopamine itself.

This explains their role in treating Parkinson's disease and restless legs syndrome. Effects on dopamine signalling can also contribute to unwanted effects such as changes in urges or behaviour.

Pramipexole tablets are indicated for Parkinson's disease and for moderate-to-severe primary restless legs syndrome. For Parkinson's disease, the label describes use in both early and advanced disease, including treatment alongside levodopa.

For restless legs syndrome, the indication specifically covers the primary form of the condition when its severity is moderate to severe. These conditions have different treatment schedules, so the prescriber selects the schedule according to the condition being treated.

The label describes oral tablets but does not list the available tablet strengths. The label lists a starting dose for Parkinson's disease with normal kidney function of 0.375 mg/day in divided doses. The label lists increases no more frequently than every 5 to 7 days, balancing benefit against adverse effects.

The label lists a maintenance range of 1.5 to 4.5 mg/day in divided doses for Parkinson's disease. Kidney impairment changes the labelled starting schedule and maximum dosage, and use in dialysis patients has not been adequately studied. The label lists a starting dose for restless legs syndrome of 0.125 mg once daily, 2 to 3 hours before bedtime.

The label lists increases every 4 to 7 days when needed, up to 0.5 mg. The label lists a longer interval of 14 days between increases for restless legs syndrome in patients with impaired kidney function.

Tablets may be used with or without food. A significant interruption in treatment may require gradual reintroduction under the prescriber's supervision.

No specific storage temperature, light or moisture conditions are listed for this product. Keep tablets in their original container, away from excess heat and moisture and out of the sight and reach of children. Follow the storage directions on the dispensing label to maintain quality.

A missed dose can interrupt symptom control. Follow the missed-dose advice in the medicine leaflet or ask a pharmacist if unsure, and do not double a dose to compensate. If treatment has been interrupted for a significant period, contact the prescriber before restarting, as the label states that gradual reintroduction may be needed.

There are no adequate data on developmental risks in pregnant women. The label states that pramipexole may cause harm to the unborn baby based on animal data.

There are no data on its presence in human milk or its effects on breastfed infants or milk production, although reduced milk production is expected because it inhibits prolactin secretion. Discuss pregnancy or breastfeeding with the prescriber, balancing the mother's treatment needs against potential risks to the baby.